Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Cellular Biomedicine Group, Inc. | cbmg_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): June 1,
2017
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36498
|
|
86-1032927
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
19925 Stevens Creek Blvd., Suite 100
Cupertino, California
|
|
95014
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (408)
973-7884
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On June 1, 2017, Cellular Biomedicine Group, Inc.
(the “Company”) authorized a share repurchase program
(the “Share Repurchase Program”), pursuant to which the
Company may, from time to time, purchase shares of its common stock
for an aggregate purchase price not to exceed $10 million. Share
repurchases may be executed in open market transactions pursuant to
a plan adopted in accordance with Rule 10b5-1 of the Securities
Exchange Act of 1934 (the “Exchange Act”) and in
accordance with Rule 10b-18 of the Exchange Act.
The authorization for the Share
Repurchase Program may be terminated by the Company in its
discretion at any time.
A copy
of the press release is attached as Exhibit 99.1 to this
report.
Item 9.01. Financial Statements and
Exhibits.
(d)
Exhibits
99.1
Press Release, dated June 1, 2017
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
|
|
|
Date:
June 1, 2017
|
By:
|
/s/ Bizuo
(Tony) Liu
|
|
|
|
|
Bizuo
(Tony) Liu
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
|